Anti‐Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits
- 12 August 2013
- journal article
- review article
- Published by Wiley in Immunology
- Vol. 140 (1), 1-11
- https://doi.org/10.1111/imm.12110
Abstract
Anti-Gal is the most abundant natural antibody in humans, constituting ~ 1% of immunoglobulins. Anti-Gal is naturally produced also in apes and Old World monkeys. The ligand of anti-Gal is a carbohydrate antigen called the 'α-gal epitope' with the structure Galα1-3Galβ1-4GlcNAc-R. The α-gal epitope is present as a major carbohydrate antigen in non-primate mammals, prosimians and New World monkeys. Anti-Gal can contributes to several immunological pathogeneses. Anti-Gal IgE produced in some individuals causes allergies to meat and to the therapeutic monoclonal antibody cetuximab, all presenting α-gal epitopes. Aberrant expression of the α-gal epitope or of antigens mimicking it in humans may result in autoimmune processes, as in Graves' disease. α-Gal epitopes produced by Trypanosoma cruzi interact with anti-Gal and induce 'autoimmune like' inflammatory reactions in Chagas' disease. Anti-Gal IgM and IgG further mediate rejection of xenografts expressing α-gal epitopes. Because of its abundance, anti-Gal may be exploited for various clinical uses. It increases immunogenicity of microbial vaccines (e.g. influenza vaccine) presenting α-gal epitopes by targeting them for effective uptake by antigen-presenting cells. Tumour lesions are converted into vaccines against autologous tumour-associated antigens by intra-tumoral injection of α-gal glycolipids, which insert into tumour cell membranes. Anti-Gal binding to α-gal epitopes on tumour cells targets them for uptake by antigen-presenting cells. Accelerated wound healing is achieved by application of α-gal nanoparticles, which bind anti-Gal, activate complement, and recruit and activate macrophages that induce tissue regeneration. This therapy may be of further significance in regeneration of internally injured tissues such as ischaemic myocardium and injured nerves.Keywords
This publication has 119 references indexed in Scilit:
- The Life History of 21 Breast CancersCell, 2012
- The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactoseJournal of Allergy and Clinical Immunology, 2011
- Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing α-gal epitopesVaccine, 2010
- Quantitative analysis by in vivo imaging of the dynamics of vascular and axonal networks in injured mouse spinal cordProceedings of the National Academy of Sciences of the United States of America, 2009
- The cancer genomeNature, 2009
- Intratumoral injection of α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activityCancer Immunology, Immunotherapy, 2009
- Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-α-1,3-galactoseJournal of Allergy and Clinical Immunology, 2008
- Modulation of the antitumor immune response by complementNature Immunology, 2008
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseNew England Journal of Medicine, 2008
- Functionally important glycosyltransferase gain and loss during catarrhine primate emergenceProceedings of the National Academy of Sciences of the United States of America, 2007